Elexacaftor/tezacaftor/ivacaftor in children aged 6–11 years with cystic fibrosis, at least one <i>F508DEL</i> allele, and advanced lung disease: A 24‐week observational study-Reference-Cited by-同舟云学术

Elexacaftor/tezacaftor/ivacaftor in children aged 6–11 years with cystic fibrosis, at least one F508DEL allele, and advanced lung disease: A 24‐week observational study

Published:2022-05-25 Issue:9 Volume:57 Page:2253-2256
ISSN:8755-6863
Container-title:Pediatric Pulmonology
language:en
Short-container-title:Pediatric Pulmonology

Author:

Salvatore Donatello¹^ORCID,Cimino Giuseppe²,Troiani Patrizia²,Bignamini Elisabetta³,Esposito Irene³,Leonetti Giuseppina⁴,Zanda Maurizio⁵,Manunza Daniela⁵,Pepe Angela¹⁶

Affiliation:

1. Cystic Fibrosis Centre, Hospital San Carlo Potenza Italy

2. Lazio Reference Centre for Cystic Fibrosis Policlinico Umberto I University Hospital Rome Italy

3. Pediatric Pulmonology Unit, Città della Salute e della Scienza Ospedale Infantile Regina Margherita Turin Italy

4. Pediatric Cystic Fibrosis Centre Azienda Universitaria Ospedaliera Consorziale Policlinico Bari Italy

5. Cystic Fibrosis Center, Azienda Ospedaliera Brotzu Cagliari Italy

6. Department of Medicine, Surgery and Dentistry, Scuola Medica Salernitana, Postgraduate School of Pediatrics University of Salerno Baronissi Italy

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ppul.25980

Reference7 articles.

1. Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

2. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

3. Burden of cystic fibrosis in children <12 years of age prior to the introduction of CFTR modulator therapies

4. Lung transplant referrals for individuals with cystic fibrosis: A pediatric perspective on the cystic fibrosis foundation consensus guidelines

5. Review of CFTR modulators 2020

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety profile of elexacaftor-tezacaftor-ivacaftor triple therapy on cystic fibrosis: a systematic review and single arm meta-analysis;Frontiers in Pharmacology;2023-12-14

2. Should all children with cystic fibrosis who have responsive CFTR mutations be prescribed CFTR modulators?;Journal of Cystic Fibrosis;2023-12

3. Cardiopulmonary Exercise Testing Provides Prognostic Information in Advanced Cystic Fibrosis Lung Disease;Annals of the American Thoracic Society;2023-10-25

4. Experience With Elexacaftor/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and Advanced Disease;Archivos de Bronconeumología;2023-09

5. Cystic fibrosis year in review 2022;Pediatric Pulmonology;2023-08-18